Investing

Sagimet Biosciences : SGMT

SGMT

Stock Data

$7.61

$0.42 (5.23%)

Asset Type

Common Stock

Exchange

NASDAQ

Currency

USD

Country

USA

Sector

HEALTHCARE

Industry

BIOTECHNOLOGY

Sagimet Biosciences Inc. is a biopharmaceutical company focused on creating treatments for diseases linked to faulty lipid metabolism. Its main project, Denifanstat, targets conditions like nonalcoholic steatohepatitis and acne through the inhibition of fatty acid synthase (FASN). Additionally, Sagimet is working on a drug for various cancers. Originally named 3-V Biosciences, it rebranded in 2019 and operates from San Mateo, California, since its founding in 2006.

All Sagimet Biosciences Articles

1 Article

Joshua Rodriguez | Aug 12, 2024 at 3:27 PM EDT

3 Penny Stocks with 190% Growth Potential According to Wall Street Analysts

Penny stocks are a fascinating category of investment opportunities. While risky, these stocks allow you to invest in companies when…